GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Gross-Profit-to-Asset %
Switch to:

Biohaven (NYSE:BHVN) Gross-Profit-to-Asset %

: 0.00% (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biohaven's annualized Gross Profit for the quarter that ended in Sep. 2022 was $0.00 Mil. Biohaven's average Total Assets over the quarter that ended in Sep. 2022 was $234.23 Mil. Therefore, Biohaven's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2022 was 0.00%.


Biohaven (NYSE:BHVN) Gross-Profit-to-Asset % Historical Data

The historical data trend for Biohaven's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Gross-Profit-to-Asset % - -

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Gross-Profit-to-Asset % Premium Member Only - - - - -

Biohaven (NYSE:BHVN) Gross-Profit-to-Asset % Competitive Comparison

For the Biotechnology subindustry, Biohaven's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven (NYSE:BHVN) Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biohaven's Gross-Profit-to-Asset % falls into.



Biohaven Gross-Profit-to-Asset % Calculation

Biohaven's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=0/( (111.499+142.061)/ 2 )
=0/126.78
=0.00 %

Biohaven's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2022 )/( (Total Assets (Q: Jun. 2022 )+Total Assets (Q: Sep. 2022 ))/ count )
=0/( (332.81+135.646)/ 2 )
=0/234.228
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Biohaven Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biohaven's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership